Pre-earnings brief
Reports
Thu, Nov 5, 2026
Est. EPS
—
Est. revenue
—
Implied move
±8.3%
EPS beat rate
13%
Vera Therapeutics, Inc. is a biotechnology company focused on developing treatments for serious diseases. Operating in the health care sector, it aims to address unmet medical needs, which is critical as the demand for innovative therapies continues to grow.
Last quarter
In Q2 2026, Vera reported an EPS of -$1.52, slightly better than the expected -$1.60. The stock reacted negatively, dropping nearly 4% the following day.
EPS beat streak
1Q
EPS beat rate
13%
Avg EPS surprise
-45.42%
Avg 1-day reaction
-1.92%
Investors are cautiously optimistic about Vera's upcoming earnings, especially after a slight improvement in EPS last quarter. However, the lack of revenue guidance raises concerns about future performance.
Bull case
If Vera can demonstrate improved revenue and continued reduction in EPS losses, it could signal a turnaround and boost investor confidence.
Bear case
Conversely, if the company fails to show progress in revenue or reports worse-than-expected losses, it could lead to further declines in stock price.
The print will turn on these.
Q1
What will the EPS figure be for Q3-2026?
The EPS result will be critical in assessing the company's financial health and ability to manage losses.
Q2
Will there be any guidance on revenue growth?
Revenue guidance is essential for understanding the company's future prospects and market position.
Est. EPS
$1.98
Est. Rev
$113.6B
Impl. Move
±6.9%
Why consensus could be wrong
The Street may be underestimating the potential for Vera to narrow its losses significantly this quarter, given recent improvements in operational efficiency.
Supporting evidence
Vera's recent EPS surprise of +5.12% indicates potential for better-than-expected performance.
The options market is pricing a larger move than historical averages, suggesting heightened investor interest.
The company's focus on innovative therapies could yield unexpected positive results.
Key risk
If EPS improves significantly, it could challenge the current negative sentiment surrounding the stock.
Pre-commit to what would confirm each case.
The core debate revolves around whether Vera can show signs of financial recovery and growth in a challenging biotech environment.
Bull confirmed if
An EPS improvement to -$1.40 or better, along with any positive revenue guidance, would confirm the bull case.
Bear confirmed if
If EPS worsens to -$1.70 or more without any revenue growth indication, it would confirm the bear case.
What the market is pricing for the move.
Implied Move
±8.32%
Historical Avg
±3.3%
The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.
Options are pricing ±8.3% while VERA has averaged ±3.3% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
57.4%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 11 of 30 (37%)
This setup has occurred 30 times across Health Care in the last 2 years. 19 of 30 (63%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 3.2%, with a raw directional average of -0.6% (modestly negative historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
118.09%
of float
Insider
0.95%
of float
Holders
311
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
5,747,760 sh · $173.9M
7.98%
13.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Vera beats expectations and raises guidance, history suggests a potential stock increase of around 3.1%, confirming a positive outlook.
In line / cautious
If results are in line but cautious commentary is provided, the stock may experience a muted reaction, reflecting uncertainty.
Miss
A miss on EPS could lead to a decline of about 1.6%, as seen in past performance, indicating ongoing concerns about the company's trajectory.
The lines on the call that would change the story.
Avoro Capital Advisors LLC
5,723,888 sh · $173.1M
7.94%
-2.8%
State Street Corporation
4,148,786 sh · $125.5M
5.76%
23.3%
Price (T.Rowe) Associates Inc
4,012,936 sh · $121.4M
5.57%
-12.3%
Deep Track Capital, Lp
4,000,000 sh · $121.0M
5.55%
-2.6%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.